Tempus AI (TEM) and Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, announced a new collaboration. The two companies ...

It was a big week for AI-focused startups with Abridge and OpenEvidence both receiving sizable funding rounds.

Ares Credit funds served as the administrative agent on the incremental debt financing, which is intended to support Tempus' acquisition of Ambry Genetics.